Overview

• Pfizer will offer most-favored-nation prices to Medicaid, aligning with the lowest levels it charges in selected high‑income countries, and said new U.S. drug launches will match those benchmarks.
• Pfizer will participate in the planned TrumpRx portal, expected in early 2026, for direct cash purchases at reported average discounts near 50% with some drugs cut by roughly 80–85%.
• In exchange, the company received a three-year exemption from threatened 100% tariffs and pledged $70 billion for U.S. manufacturing and research.
• Officials provided few details on timing and scope beyond Medicaid and direct sales, and experts cautioned that many insured patients may not see lower out‑of‑pocket costs.
• The administration says additional manufacturer agreements are being pursued, with pricing changes and TrumpRx access slated to phase in next year.